Phase II Study of Mafosfamide in Progressive Advanced Renal Cell Carcinoma
Ch. Schöber(Palmetto Hematology Oncology), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Stefan Schmidt(Innsbruck Medical University), H. Wilke(Palmetto Hematology Oncology), H. Poliwoda, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), A. Harstrick(Merck KGaA, Darmstadt (Germany)), Udo Jonas
Cited by 1
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
|Journal of Clinical Oncology|2005|491